GenVault Provides GenTegra(TM) DNA to Support Cardiovascular Genetic Testing at Berkeley HeartLab

CARLSBAD, Calif., March 17 /PRNewswire/ -- GenVault Corporation today announced that Berkeley HeartLab, a subsidiary of Celera Corporation (Nasdaq: CRA), has adopted GenTegra DNA to preserve and store diagnostic samples for genetic testing related to the management of cardiovascular disease.  

As new clinically important diagnostic genetic markers are introduced, such as KIF6 and LPA, accessing stored DNA eliminates the need to collect a new sample and facilitates return of potentially critical medical information back to the physician.  Currently, Berkeley HeartLab offers 39 individual clinical laboratory tests.

"GenVault is excited to partner with Berkeley HeartLab in the application of our GenTegra technology in support of diagnostic genetic testing," said David Wellis, Ph.D., President and CEO at GenVault.  "Berkeley HeartLab's extensive and successful validation of GenTegra within their CLIA-certified and CAP-accredited laboratory is testimony to the robustness and quality of GenVault's technologies in managing clinical samples."

"At Berkeley HeartLab, the further integration of genetic tests into the standard panels of cardiovascular diagnostics requires efficient, high quality DNA handling and management," said Jean Amos Wilson, Ph.D., Vice President of Laboratory Operations at Berkeley HeartLab. "GenVault's GenTegra DNA provides a robust infrastructure for supporting our genetic testing business."

About GenTegra Technology

GenTegra™ technology is an innovation in stabilizing biosamples comprised of inert chemical matrix with built-in oxidative protection and antimicrobial activity for dry, room temperature transport and biobanking of purified DNA.  GenTegra DNA is provided in ready to use aliquots, and purified DNA dried within GenTegra DNA is simply and fully resolubilized with water for direct downstream molecular analysis.

About GenVault Corporation

GenVault provides risk free biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification.  GenVault is empowering pharmaceutical companies, medical centers, academic institutions and law enforcement agencies to more fully leverage the rapidly growing genomics industry. As a scalable, reliable and environmentally friendly alternative to traditional freezers and nucleic acid purification systems, the company's dry-state platform enables the extraction, preservation, recovery, and distribution of biosamples at ambient temperature.  From GenPlates to the Dynamic Archive, GenVault is continuously developing and refining best practices for biosample management and preservation. For more information visit GenVault at www.genvault.com.

About Berkeley HeartLab and Celera

Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Rene Nunez

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=92778

SOURCE GenVault Corporation